Fenwick Represents Hikma Ventures in Investment in Altoida

Fenwick & West represented Hikma Ventures, the strategic venture capital arm of Hikma Pharmaceuticals PLC, in its investment in Altoida, Inc. (following the company’s Series A financing round which closed in 2019).

Altoida is a health technology firm with an FDA-cleared and CE Mark-approved medical device and brain health data platform designed to support the early detection of Alzheimer's disease up to ten years prior to onset. More information about the investment can be obtained from Hikma Ventures’ announcement​.

The Fenwick transaction team included corporate partner Ian Goldstein and associate Alina Azizian, along with intellectual property associate Pinar Bailey.